<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)
November 10, 2000 (November 7, 2000)
OMNI NUTRACEUTICALS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
UTAH 0-18160 87-046822
-------------------------------- --------------- ----------------------
(STATE OF OTHER JURISDICTION (COMMISSION (IRS EMPLOYER
OF INCORPORATION) FILE NUMBER) IDENTIFICATION NO.)
5310 BEETHOVEN STREET
LOS ANGELES, CA 90066
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (310) 306-3636
N/A
(FORMER NAME AND FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
1
<PAGE>
OMNI NUTRACEUTICALS, INC.
TABLE OF CONTENTS
FOR
CURRENT REPORT ON FORM 8-K
Page No.
--------
Item 5. Other Events 3
Item 7. Exhibits 3
Signature
2
<PAGE>
ITEM 5
OTHER EVENTS
The Company announced on November 7, 2000 that the Nasdaq stock market had
halted the trading in the shares of the company's stock until the company has
satisfied a request for additional information. The trading halt was related to
Omni's announcement, made back on October 17 and in an 8-K filing on November
2,2000, that previously reported financial results would require restatement,
resulting in the company's former auditors withdrawing their opinion on the
company's fiscal 1999 financial statements.
A copy of the press release is attached hereto as an Exhibit.
ITEM 7
EXHIBITS
10.28 Press Release-November 8, 2000.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
OMNI NUTRACEUTICALS, INC.
Date: November 13, 2000 By: /s/ KLEE IRWIN
-----------------------
Klee Irwin
Chief Executive Officer
3
